转移性心肌病中的遗传多样性和分子机制:走向个性化治疗
Komal Marwaha1,2, Behram Mody3, Nathan Holland1
1Paul L Foster School of Medicine, Texas Tech University Health Science Center, El Paso, TX, USA.
American journal of physiology. Heart and circulatory physiology
|January 28, 2026
概括
超性心肌病变 (HCM) 是一种常见的遗传性心脏疾病. 本综述将遗传因素,分子途径和新疗法联系起来,以更好地理解和治疗HCM,旨在准确医学.
科学领域:
- 心血管遗传学 心血管遗传学
- 分子心脏病学分子心脏病学
- 精准医学是一门精准的医学.
背景情况:
- 增高性心肌病变 (HCM) 是最常见的遗传性心脏病.
- 目前的研究缺乏一个统一的模型,用于不同的遗传原因和多样化的表型.
- 了解基因架构在HCM病原发生中的作用至关重要.
研究的目的:
- 综合当前关于遗传因素,分子途径和HCM新兴疗法的研究.
- 阐明遗传多样性如何影响疾病透率和临床表现.
- 建立一个基于机制的HCM管理和研究框架.
主要方法:
- 关于sarcomeric和non-sarcomeric突变的全面审查,包括中间效果变体和多基因修饰剂.
- 对遗传多样性与关键分子通路 (例如,处理,线粒体功能,信号通路) 的交集分析.
- 评估新兴的基于机制的疗法 (例如,肌抑制剂,基因沉默,CRISPR).
主要成果:
- 遗传多样性,包括取决于祖先的错误分类,显著影响HCM的透率和表达.
- 分子路径,如体超收缩性,失调和改变的信号驱动高和纤维性重塑.
- 新兴疗法针对上游分子驱动器,为基于机制的治疗提供了潜力.
结论:
- 连接遗传架构,分子致病和有针对性的干预措施的凝聚性框架对于推进HCM护理至关重要.
- 解决诸如VUS分类,数据库偏差和基因疗法安全等挑战对于精准医学集成至关重要.
- 未来的研究应该集中在特定途径的治疗方法,变异验证和增强的表型化,以改善HCM建模和治疗.
相关概念视频
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
483
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
483
02:50Combination Therapies and Personalized Medicine
6.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.1K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
557
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
557
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
526
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
526
00:59Gene Therapy
27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
00:49What is Genetic Engineering?
80.1K
Overview
80.1K